top of page

Tubulis and Bristol Myers Squibb: A Strategic Alliance for Ground-Breaking Cancer Treatment


A revolutionary collaboration has been announced between Tubulis, a German biopharmaceutical firm, and Bristol Myers Squibb (BMS), a renowned pharmaceutical company based in the United States. This joint venture aims to develop advanced antibody-drug conjugates (ADCs) intended for the treatment of various cancer types.

Understanding the Concept of ADCs

Antibody-drug conjugates (ADCs) are a unique class of medicines designed to deliver potent chemotherapy drugs directly to cancer cells, thereby reducing harm to healthy cells. Unlike traditional chemotherapy treatments, ADCs offer a more targeted approach, delivering the chemotherapy via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.

ADCs bind to the target (cancer protein or receptor), then release a cytotoxic drug into the cancer cell, effectively killing it.

Tubulis' Role in the Collaboration

As part of the agreement, Tubulis will provide BMS with access to its proprietary technology platforms, Tubutecan and P5. These innovative platforms enable the creation of site-specific conjugates with improved therapeutic properties, creating a new frontier in the field of cancer treatment.

BMS: A Brief Overview

Bristol Myers Squibb Co., established in 1887, is a pharmaceutical titan headquartered in New York, United States. With a diverse portfolio of treatment development for numerous diseases including neoplasms, immune system diseases, and digestive system disorders, BMS has made significant strides in the world of healthcare.

BMS is publicly traded on the New York Stock Exchange under the symbol BMY. Their drug development efforts primarily revolve around small molecule drugs and monoclonal antibodies, with a growing focus on developing drugs targeting specific proteins such as CRBN, BCMA, PD-1, CD19, and PDL1.

Global Progress in ADC Development

According to the Synapse drug intelligence database, the leading five institutions in global ADC development progress are Takeda Pharmaceutical Co., Ltd., BSP Pharmaceuticals SpA, Rakuten Medical, Inc., GSK Plc, and Acino International AG.

The top five targets in global ADC development progress are Tubulin, HER2, DNA, TOP1, and CD22, with the top five indications being Breast cancer, HER2-positive breast cancer, Diffuse large B-cell lymphoma, Urothelial carcinoma, and HER2-positive gastric cancer.

The Impact of the Collaboration

This collaboration between Tubulis and BMS represents a monumental leap in the development of next-generation ADCs for cancer treatment. By combining Tubulis' innovative technology platform with BMS' extensive experience in oncology drug development, the partnership aims to accelerate the discovery and development of more effective, safer, and more accessible therapies for cancer patients.


Indications for ADCs in development include Neoplasms, Digestive System Disorders, and Breast Cancer.


With the power of Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform, strategic R&D decisions can be made swiftly. This collaboration between Tubulis and BMS is a testament to how strategic alliances can potentially revolutionize areas of healthcare, particularly in the domain of cancer treatment.


This article is for informational purposes only. Please consult a healthcare professional for medical advice.


Recent Posts

See All

Biogen's Acquisition of Reata Pharmaceuticals

Introduction In a significant development for the medical community, Biogen Inc. (Nasdaq: BIIB) has announced its definitive agreement to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA). This strat


bottom of page